1. Home
  2. FNWB vs RLYB Comparison

FNWB vs RLYB Comparison

Compare FNWB & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Northwest Bancorp

FNWB

First Northwest Bancorp

HOLD

Current Price

$11.01

Market Cap

96.3M

Sector

Finance

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$16.12

Market Cap

86.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNWB
RLYB
Founded
1923
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
96.3M
86.6M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
FNWB
RLYB
Price
$11.01
$16.12
Analyst Decision
Buy
Analyst Count
1
0
Target Price
$13.50
N/A
AVG Volume (30 Days)
21.4K
38.2K
Earning Date
04-29-2026
05-11-2026
Dividend Yield
0.70%
N/A
EPS Growth
36.00
N/A
EPS
0.04
6.16
Revenue
$176,000.00
$858,000.00
Revenue This Year
$19.24
N/A
Revenue Next Year
$8.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
43.00
52 Week Low
$7.05
$0.40
52 Week High
$12.52
$17.57

Technical Indicators

Market Signals
Indicator
FNWB
RLYB
Relative Strength Index (RSI) 40.42 54.70
Support Level $9.37 $15.60
Resistance Level $11.51 $16.50
Average True Range (ATR) 0.37 0.46
MACD -0.16 -0.06
Stochastic Oscillator 4.59 27.42

Price Performance

Historical Comparison
FNWB
RLYB

About FNWB First Northwest Bancorp

First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It offers various products and services, such as commercial business loans, multi-family real estate loans, auto and consumer loans, transaction accounts, savings and money market accounts, online banking services, etc., focused on the lending, deposit, and money movement needs of individuals, businesses and nonprofit organizations. The Group's operations are mainly focused on serving various communities in Washington State, U.S. Substantially all of its income is derived from a diverse base of commercial, mortgage, and consumer lending activities and investments.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: